biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tuck	12/8/2006 12:20:31 PM
	Read Replies (3) of 3661

Genta (GNTA) off 18% to definite penny stock levels as Genasense whiffs in yet another indication. Will these guys ever give up? How many more shots on goal from the penalty box do they have? >>9:00AM Genta announces Phase 3 Trial of Genasense in older patients with acute myelogenous failed to meet its primary endpoint of overall survival (GNTA) 0.81 : Co announced that the co has been notified of preliminary results from a randomized Phase 3 trial of chemotherapy with or without Genasense Injection that was conducted in older, previously untreated patients with acute myelogenous leukemia. According to the analysis conducted by the Cancer and Leukemia Group B, the trial failed to meet its primary endpoint of overall survival. Further analyses of these data will be submitted for presentation at a scientific meeting. This study was sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute, under a Cooperative Research and Development Agreement between Genta and N.C.I.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next